Hypertension
Conditions
Interventions
Sponsors
Control of organ function, Kanazawa University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Hypertensive patients who did not reach the recommendation of Hypertension Guidelines issued by Japanese Association of Hypertension 2009 2)Without taking RAAS inhibitor 3)Both inpatient and out patient 4)Subjects who gave written informed consent
Exclusion criteria
Exclusion criteria: 1)Pregnancy or Breastfeeding 2)Malignant hypertension, secondary hypertension 3)Patients with severe cardiovascular deseases or history(history of acute coronary syndrome, stroke within 6 month) 4)Patients with severe liver damage 5)Hypersensitivity of aliskiren or valsartan 6)Patients who receive Hormone replacement therapy 7)Anyconditions not suitable for the participation in this trial judged by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma aldosterone concentration, Plasma renin activity Blood pressure(On visit/Home monitoring) Improvement of hypertensive target organ damage measured as urinary albumin excretion ratio | — |
Secondary
| Measure | Time frame |
|---|---|
| Ambulatory blood pressure monitoring Chages in left ventricular hypertrophy(electrocardiogram and echocardiography) | — |
Countries
Japan
Outcome results
None listed